Pubblicazioni

Autori:

Sacconi, Riccardo; Battaglia Parodi, Maurizio; Casati, Stefano; Lattanzio, Rosangela; Marchini, Giorgio; Bandello, Francesco

Titolo:

Dexamethasone implants in diabetic macular edema patients with high visual acuity

Anno:

2017

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

A Stampa

Referee:

Sì

Nome rivista:

OPHTHALMIC RESEARCH

ISSN Rivista:

0030-3747

N° Volume:

58

Numero o Fascicolo:

3

Intervallo pagine:

125-130

Parole chiave:

Dexamethasone; diabetic retinopathy; high visual acuity; macular edema; optical coherence tomography; Ozurdex

Breve descrizione dei contenuti:

PURPOSE: To evaluate the effects of intravitreal dexamethasone (DEX) implants in patients affected by diabetic macular edema (DME) with high best-corrected visual acuity (BCVA) and contraindications to therapy with anti-vascular endothelial growth factor over a 12-month follow-up. METHODS: In this interventional nonrandomized clinical study, 14 consecutive patients (14 eyes) affected by DME with a BCVA of 0.3 LogMAR or better were prospectively enrolled. All patients were treated with a sustained-release 700-μg DEX implant at baseline, revaluated every 6 weeks, and retreated on a pro re nata basis. Primary outcomes included changes in BCVA and central macular thickness (CMT). Secondary outcomes included number of implants, average period between injections, and incidence of side effects. RESULTS: At the 12-month examination, a significant improvement in mean BCVA was noted compared to baseline (from 0.25 ± 0.05 to 0.10 ± 0.07 LogMAR; p < 0.001); CMT decreased from 484 ± 127 to 311 ± 51 μm (p < 0.001). No differences in BCVA and CMT improvements were found between treatment- naïve patients and previously treated patients (p = 0.768 and 0.119, respectively). The mean number of implants was 1.71 ± 0.61 (range, 1-3). The mean period between the first and the second implant was 6.1 ± 1.6 months. CONCLUSIONS: The DEX implant on a pro re nata basis can be considered a beneficial approach for DME patients with high BCVA over a 12-month follow-up; functional and anatomical outcome of the patients significantly improved with few injections and a good safety profile.

Pagina Web:

https://doi.org/10.1159/000477256

Id prodotto:

98870

Handle IRIS:

11562/968511

ultima modifica:

13 novembre 2022

Citazione bibliografica:

Sacconi, Riccardo; Battaglia Parodi, Maurizio; Casati, Stefano; Lattanzio, Rosangela; Marchini, Giorgio; Bandello, Francesco, Dexamethasone implants in diabetic macular edema patients with high visual acuity «OPHTHALMIC RESEARCH» , vol. 58 , n. 3 , 2017 , pp. 125-130

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo